5-HT2A receptor antagonists and TPH inhibitors (e.g., LX1032) are being explored to inhibit 5-HT synthesis or pathogenic signalling, thereby mitigating airway hyperresponsiveness. Here, TPH1 is linked to airway hyperresponsiveness.